Literature DB >> 28881886

Monitoring sputum culture in resected esophageal cancer patients with preoperative treatment.

K Kosumi1, Y Baba1, K Yamashita1, T Ishimoto1, K Nakamura1, M Ohuchi1, Y Kiyozumi1, D Izumi1, R Tokunaga1, K Harada1, H Shigaki1, J Kurashige1, M Iwatsuki1, Y Sakamoto1, N Yoshida1, M Watanabe2, H Baba1.   

Abstract

Pneumonia is a major cause of postesophagectomy mortality and worsens the long-term survival in resected esophageal cancer patients. Moreover, preoperative treatments such as chemotherapy or chemoradiotherapy (which have recently been applied worldwide) might affect the bacterial flora of the sputum. To investigate the association among preoperative treatments, the bacterial flora of sputum, and the clinical and pathological features in resected esophageal cancer patients, this study newly investigates the effect of preoperative treatments on the bacterial flora of sputum. We investigated the association among preoperative treatments, the bacterial flora of sputum, and clinical and pathological features in 163 resected esophageal cancer patients within a single institution. Pathogenic bacteria such as Candida (14.1%), Staphylococcus aureus (6.7%), Enterobacter cloacae (6.1%), Haemophilus parainfluenzae (4.9%), Klebisiella pneumoniae (3.7%), Methicillin-resistant Staphylococcus aureus (MRSA) (3.7%), Pseudomonas aeruginosa (2.5%), Escherichia coli (1.8%), Streptococcus pneumoniae (1.8%), and Haemophilus influenzae (1.2%) were found in the sputum. The pathogen detection rate in the present study was 34.3% (56/163). In patients with preoperative chemotherapy and chemoradiotherapy, the indigenous Neisseria and Streptococcus species were significantly decreased (P= 0.04 and P= 0.04). However, the detection rates of pathogenic bacteria were not associated with preoperative treatments (all P> 0.07). There was not a significant difference of hospital stay between the sputum-monitored patients and unmonitored patients (35.5 vs. 49.9 days; P= 0.08). Patients undergoing preoperative treatments exhibited a significant decrease of indigenous bacteria, indicating that the treatment altered the bacterial flora of their sputum. This finding needs to be confirmed in large-scale independent studies or well-designed multicenter studies.
© The Authors 2017. Published by Oxford University Press on behalf of International Society for Diseases of the Esophagus. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.

Entities:  

Keywords:  complication; esophageal cancer; esophagectomy; pneumonia; preoperative treatment

Mesh:

Year:  2017        PMID: 28881886     DOI: 10.1093/dote/dox092

Source DB:  PubMed          Journal:  Dis Esophagus        ISSN: 1120-8694            Impact factor:   3.429


  4 in total

1.  FLOT (a chemotherapy regimen for gastric/esophagogastric junction cancer): to be treated as a highly emetogenic regimen or a moderately emetogenic one? Comparison of the emetogenic potential of FLOT versus FOLFOX and TAC regimens.

Authors:  Marziyeh Ghorbani; Mehdi Dehghani; Noushin Fahimfar; Soha Namazi; Ali Dehshahri
Journal:  Support Care Cancer       Date:  2022-01-17       Impact factor: 3.603

2.  Clinical usefulness of a perioperative bacteriological culture to treat patients with postoperative pneumonia after esophagectomy.

Authors:  Tomoyuki Matsunaga; Hiroshi Miyata; Keijiro Sugimura; Kei Asukai; Yoshitomo Yanagimoto; Yusuke Takahashi; Akira Tomokuni; Kazuyoshi Yamamoto; Hirofumi Akita; Junichi Nishimura; Hiroshi Wada; Hidenori Takahashi; Masayoshi Yasui; Takeshi Omori; Masayuki Oue; Masahiko Yano
Journal:  Ann Gastroenterol Surg       Date:  2018-09-21

3.  Microbiota of the Oropharynx and Endoscope Compared to the Esophagus.

Authors:  Ikenna C Okereke; Aaron L Miller; Catherine F Hamilton; Adam L Booth; Gabriel L Reep; Clark L Andersen; Sandy T Reynolds; Richard B Pyles
Journal:  Sci Rep       Date:  2019-07-15       Impact factor: 4.379

4.  Preoperative bacterial culture can predict severe pneumonia in patients receiving esophagectomy.

Authors:  Akinao Kaneta; Takahiro Sato; Hiroshi Nakano; Takuro Matsumoto; Takeshi Tada; Yohei Watanabe; Hiroyuki Hanayama; Suguru Hayase; Zenichiro Saze; Koji Kono
Journal:  Fukushima J Med Sci       Date:  2022-08-05
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.